ArticleJournal of neurology2026
Anti-NMDA receptor encephalitis outcomes in a population-based cohort.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePrior studies of anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDARE) may have overestimated poor long-term outcomes and relapse rates and underestimated mortality because they were conducted in referral centers. Our objective was to evaluate these outcomes in a population-based cohort.
methodsWe performed a retrospective study of patients with new-onset anti-NMDARE between 2009 and 2022 from the population-based membership of Kaiser Permanente Southern California. All covariates and outcomes were obtained from electronic health records through December 31, 2024.
resultsSeventy-two patients with NMDARE (n = 49, 68% 2014-2022) were identified; of whom 65.3% were female, the median age was 24.5 years, and only 8.3% identified as white, non-Hispanic. First-line immunotherapy was initiated early (median 19 days from symptom onset) and 46 (63.8%) received second-line therapy with rituximab alone (n = 32) or in combination with cyclophosphamide (n = 13). After a median follow-up of 4.7 years (IQR 2.9-9.0), favorable outcomes (modified Rankin Scale ≤ 2) improved from 22% at hospital discharge to 84.5% at the most recent follow-up. Relapses were uncommon (4.1%). Overall mortality declined from 17.4% in 2009-2013 to 4.1% in 2014-2022. Initiation of rituximab within 2 months of symptom onset, increased from 63.6% in 2009-2013 to 82.9% in 2014-2022. DISCUSSION: In this population-based cohort of new-onset NMDARE patients, the risk of relapses was lower and long-term functional outcomes were better than previously reported. Mortality was high before 2014 and declined significantly thereafter, paralleling the increase in rapid escalation to rituximab in patients with inadequate responses to first-line treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.